SCHEDULE 13G/A: Adage Capital Management Discloses 1.07% Stake in Mereo BioPharma Group plc
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed an amended Schedule 13G disclosing a 1.07% beneficial ownership stake in Mereo BioPharma Group plc.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Mereo BioPharma Group plc.
- The Reporting Persons collectively beneficially own 8,503,780 Ordinary Shares of Mereo BioPharma Group plc.
- This ownership represents 1.07% of the company's outstanding Ordinary Shares.
- The percentage is calculated based on 795,001,444 Ordinary Shares outstanding as of March 25, 2025, as reported in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- Adage Capital Management, L.P. is a Delaware limited partnership, while Robert Atchinson and Phillip Gross are citizens of the United States.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded biopharmaceutical company. It reflects an investment position rather than operational or strategic insights into the company or the broader industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for Mereo BioPharma Group plc's Annual Report on Form 10-K. |
| 2025-03-25 | Date as of which 795,001,444 Ordinary Shares were reported outstanding in the Company's 10-K. |
| 2025-03-26 | Date Mereo BioPharma Group plc's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, was filed with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-12 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Mereo BioPharma Group plc, Adage Capital Management, Schedule 13G, Beneficial Ownership, MREO, Biopharma, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.